Deal Watch: Bristol, Janssen Keep The Heat High In Cancer Immunotherapy Deal-Making
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.
You may also be interested in...
Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned
Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.
Hikma To Buy Bedford, Transfer Manufacturing For U.S. Generics Injectables
Ben Venue’s shuttered Ohio plant is also slated to be part of the transaction, but Hikma’s initial focus is on moving acquired assets into its production facilities, even though the Jordan-based firm expects only limited revenue from them over the next two years.
Pfizer, Boehringer Ingelheim Tap MacroGenics In Separate Deals
The startup strikes a two-drug oncology deal with Pfizer and a ten-target agreement with BI just days after Lilly halted development of its lead compound.